Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 35K
5: R1 Cover Page HTML 45K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- icui-20220517_htm XML 21K
7: EXCEL IDEA Workbook of Financial Reports XLSX 6K
3: EX-101.LAB XBRL Labels -- icui-20220517_lab XML 67K
4: EX-101.PRE XBRL Presentations -- icui-20220517_pre XML 33K
2: EX-101.SCH XBRL Schema -- icui-20220517 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 16K
10: ZIP XBRL Zipped Folder -- 0000883984-22-000032-xbrl Zip 12K
Registrant's telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading Symbol
Name of each exchange on which registered
iCommon stock, par value $0.10 per share
iICUI
iThe
Nasdaq Stock Market LLC
(Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
i☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
At the 2022 annual meeting of stockholders of ICU Medical, Inc. (the "Company") held on May 17, 2022, the following proposals were voted on by the Company’s stockholders, and the results were as set forth below:
Proposal 1. Election of directors.
Name
of Nominee
Votes For
Withheld
Broker Non-Votes
Vivek Jain
20,884,442
507,092
761,531
George A. Lopez, M.D.
21,336,260
55,274
761,531
David
C. Greenberg
21,111,298
280,236
761,531
Elisha W. Finney
20,928,741
462,793
761,531
David F. Hoffmeister
19,888,047
1,503,487
761,531
Donald
M. Abbey
21,018,209
373,325
761,531
Laurie Hernandez
21,377,083
14,451
761,531
Kolleen T. Kennedy
21,378,371
13,163
761,531
William
Seeger
21,377,964
13,570
761,531
The Company’s stockholders elected each of the director nominees to serve as a director until the next annual meeting of stockholders or until their respective successors are elected and qualified.
Proposal 2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31,
2022.
Votes For
Votes Against
Abstain
Broker Non-Votes
21,245,122
901,415
6,528
—
The
Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.
Proposal 3. Approve the advisory vote on the Company’s named executive officer compensation.
Votes
For
Votes Against
Abstain
Broker Non-Votes
21,178,194
200,369
12,971
761,531
The Company’s stockholders approved, on an advisory basis, the
Company’s named executive officer compensation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
